@article {McCrae358, author = {Keith McCrae}, title = {Immune thrombocytopenia: No longer {\textquoteleft}idiopathic{\textquoteright}}, volume = {78}, number = {6}, pages = {358--373}, year = {2011}, doi = {10.3949/ccjm.78gr.10005}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/78/6/358}, eprint = {https://www.ccjm.org/content/78/6/358.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }